Loading stock data…
IMMP
$0.46+0.03 (+5.73%)
After Hours$0.46+0.00 (+0.37%)· Last close May 4
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immutep Limited in the Healthcare sector is trading at $0.46. The stock is currently near its 52-week low of $0.29, remaining 75.5% below its 200-day moving average. Technical signals show neutral RSI of 65 and bullish MACD crossover, explaining why IMMP maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 65) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.46
Potential Upside
5%
Whystock Fair Value$0.48
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$84.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-62.12%
Volume
Today's trading volume
990,462
Recent News
Immutep Limited (IMMP) Receives FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Immutep Limited is among the oversold stocks to invest in now. TheFly reported on April 15 that IMMP announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to eftilagimod alfa (efti) for the treatment of Soft Tissue […]
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index down 0.5% an
Sector Update: Health Care Stocks Lower in Afternoon Trading
Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index and the State Str
Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.Claim 30% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Top 5 Upgrades: HSBC upgraded Nio (NIO) to Buy from Hold with a price target of $6.80, up from $4.80.
Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination
The company will now assess the available data to determine its next steps in progressing efti’s development across multiple solid tumour indications.